---
title: "The CEO of Roche stated in response to the U.S. tariff issue: \"We have increased our production and "
description: "The CEO of Roche stated in response to the U.S. tariff issue: \"We have increased our production and inventory levels in the United States.\""
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262351869.md"
published_at: "2025-10-23T05:47:51.000Z"
---

# The CEO of Roche stated in response to the U.S. tariff issue: "We have increased our production and 

> The CEO of Roche stated in response to the U.S. tariff issue: "We have increased our production and inventory levels in the United States."

The CEO of Roche stated in response to the issue of U.S. tariffs: "We have increased our production and inventory levels in the United States."

### Related Stocks

- [RHHBY.US - Roche](https://longbridge.com/en/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates | Fitch Maintains Ratings of Hikma, Roche Following Corporate Rating Criteria Updates | [Link](https://longbridge.com/en/news/275874477.md) |
| Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/en/news/276097246.md) |
| Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/en/news/276037536.md) |
| Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/en/news/276037337.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/en/news/276037735.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.